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The gene-environment interaction before birth is just us, if not more, important than the gene-1 
lifestyle interaction after birth in setting a risk of disease in later life through a process known 2 
as developmental programming (1).  The best evidence in humans to support developmental 3 
programming comes from studies of obese women who have fallen pregnant before and after 4 
having bariatric surgery (2). These studies show that siblings born before the surgery have an 5 
increased risk of cardiometabolic disease compared to those born after. Therefore, such 6 
studies underscore that alterations in the environment at critical periods of intrauterine 7 
development even within the same womb can directly influences long-term cardiovascular 8 
health in offspring of the same family.  Consequently, there has been an exponential growth 9 
of studies in this field of developmental programming aiming to identify underlying 10 
mechanisms and thereby treatment, most recently focussed on improving precision medicine 11 
by applying basic principles of personalised medicine to intrauterine therapy (3).  Two 12 
relevant examples are provided by studies aiming to improve organelle-targeted therapy (4-6) 13 
and by the growing awareness that the sex of the offspring and of its placenta ought to be 14 
included as biological variables into experimental design and analysis when studying 15 
vertebrate animals and humans (7-9). 16 
 
A cluster of recent studies have aimed to improve precision intrauterine medicine by 17 
employing mitochondria-targeted, rather than conventional, antioxidants to protect against 18 
cardiovascular dysfunction programmed in offspring by chronic fetal hypoxia, one of the 19 
most common complications in human pregnancy (4-6).  An interesting discussion is brewing 20 
comparing mitochondria-targeted antioxidant therapy directly to the fetus, or treatment 21 
specifically to the placenta.  Studies using the chicken embryo show that direct in ovo 22 
administration of the mitochondria-targeted antioxidant MitoQ prevented in vivo 23 
mitochondria-derived oxidative stress and protected against cardiac mitochondrial 24 
dysfunction, and impaired cardiac and endothelial function in the chronically hypoxic 25 
chicken embryo (4).  Further, studies in sheep show that maternal systemic treatment with 26 
MitoQ crosses the placenta, increases MitoQ uptake into the fetal tissues and prevents 27 
programmed hypertension in the adult offspring (4).  Combined, therefore, studies in the 28 
chicken embryo and in the sheep show that mitochondria-targeted therapy to the hypoxic 29 
fetus prevents programmed cardiovascular disease in the adult offspring (4).  Conversely, 30 
there have been recent studies in rats, which have developed a placenta-targeted treatment 31 
strategy using MitoQ encapsulated into nanoparticles (nMitoQ).  The aim is to protect against 32 
placental oxidative stress while preventing passage of the prenatal therapy into the fetal 33 
circulation, thereby avoiding potential adverse off-target effects on the fetus (6).  These 34 
studies have also reported improved placental function and protection against cardiovascular 35 
dysfunction in adult offspring of hypoxic pregnancy (6).    36 
  
Similarly, there has been a growing awareness in the field of developmental programming 37 
that not only the sex of the fetus, but also of its placenta, can influence susceptibility to 38 
adverse intrauterine conditions and strategies to combat complications during pregnancy.  39 
Generally, it is widely accepted that the male fetus is at greater risk morbidity and mortality 40 
in human complicated pregnancy (7).  Clifton and colleagues have reported that in human 41 
pregnancies complicated by asthma, changes in placental function occur in a sex-specific 42 
manner, resulting in differences in fetal development, which influence child health (8).  43 
While the male placenta adapts function to maintain fetal growth at any cost, the female 44 
placenta triggers adaptations to budget resources and slow fetal growth, harnessing energy to 45 
survive a secondary insult (8). Evans & Myatt (9) have also reported that the male fetus of a 46 
lean woman has the greatest antioxidant activity, and that this protection is lost with 47 
pregnancy complicated by maternal obesity. 48 
 
In this issue of Pediatric Research, Wilson and colleagues (10), in an elegant study report 49 
sexual dimorphism in the gene expression of the brain in a model of fetal growth restriction 50 
by maternal nutrient restriction in the guinea pig.  In pregnancy complicated by fetal growth 51 
restriction, inflammatory marker mRNA expression in the fetal brain was significantly higher 52 
in females compared to males.  This provides evidence to refute the belief that it is always the 53 
male progeny that is at increased risk during complicated pregnancy.  The authors suggest 54 
that differences in gene expression between males and females may confer a selective 55 
advantage or disadvantage during adverse intrauterine conditions (10).  Their studies also 56 
show that treatment of the placenta with a nanoparticle known to increase insulin-like growth 57 
factor 1 expression, can not only protect fetal growth by increasing nutrient transporter 58 
expression and placental angiogenesis in adverse pregnancy, but that it can also affect mRNA 59 
expression in the brain of the offspring in a sex-specific manner. Of most interest, despite 60 
only directly affecting the placenta, nanoparticle treatment resulted in changes in fetal brain 61 
mRNA expression of the inflammatory markers Tgfβ and Ctgf, so that expression was similar 62 
between male and female fetuses in the nutrient-restricted groups (10).  Combined, therefore, 63 
the observations in the study of Wilson et al. (10), provide a good example working towards 64 
precision medicine in field of developmental programming, not only by using targeted 65 
therapy, but also by doing so using an experimental design that includes the sex of the fetus 66 
and of its placenta as biological variables.  Only adopting such approaches, will real advances 67 
be made to expedite translational discoveries and isolate optimal therapy to improve the 68 
health of pregnant women and their children.   69 
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